For patients with HER2-negative advanced GC or GEJC, fluoropyrimidine and platinum-based chemotherapy remains the first-line treatment (National Comprehensive Cancer Network, 2024; Lordick et al., 2022). This evidence concerns the gene ERBB2 and gastric cancer.